In a report released earlier today, Dougherty & Company LLC reiterated its Buy rating for Mednax, Inc. MD but dropped its price target from $100.00 to $80.00.
Dougherty & Company said their decision “assumes investors will put an Enterprise Value on MD of approximately 8.0x our 2012 adjusted EBITDA forecast ($438 million). This seems reasonable in light of the company's leadership position, track record and growth prospects. In addition, it is lower than the multiple (10x) paid recently by a large, experienced private equity group to take Emergency Medical Services Corp. (EMS – NR) private. EMS is not a perfect comp for MD but it is as good a one as is available now.”
Mednax, Inc. closed on Friday at $65.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in